Quality of Life in Patients with Pancreatic Cancer before and during the COVID-19 Pandemic.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
21 03 2022
Historique:
received: 21 02 2022
revised: 13 03 2022
accepted: 18 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 1 4 2022
Statut: epublish

Résumé

Coronavirus disease 19 (COVID-19) substantially affects cancer patients due to adverse outcomes and disruptions in cancer care. Recent studies have indicated the additional stress and anxiety burden arising from the pandemic and impairing quality of life in this vulnerable group of patients. However, patients with cancer represent a heterogenous group. Therefore, we conducted a study on patients with pancreatic cancer, requiring demanding surgical interventions and chemotherapy regimens due to its aggressive tumor biology, to explore the pandemic's impact on quality of life within this homogenous cohort. In a descriptive observational study, the quality of life of patients who had undergone pancreatic surgery for tumor resection at our institution between 2014 and the beginning of the pandemic in March 2020 was assessed. For HRQoL measurement, we used the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), comparing their situation before the pandemic and since its beginning. An additional self-developed questionnaire was applied to assess the life circumstances during the pandemic. Our cohort included 26 patients. Scores from the survey in HRQoL revealed no significant changes over time between before and during the pandemic. A medium deterioration in HRQoL was apparent in social functioning, as well as a small deterioration in role functioning and emotional functioning. Worries concerning a potential impact of COVID-19 on personal health were expressed. Psychological limitations in QoL were mainly attributed to the pandemic, whereas physical limitations in QoL were rather associated with the underlying disease of pancreatic cancer. The COVID-19 pandemic is causing considerable social and emotional distress among pancreatic cancer patients. These patients will benefit from psychological support during the pandemic and beyond. Long-time survivors of pancreatic cancer, such as those included in our cohort, appear to have improved resilience facing the psychosocial challenges of the pandemic. For pancreatic cancer, surgical care is considered the cornerstone of treatment. Prolonged delays in healthcare cause serious damage to mental and physical health. To date, the longer-term clinical consequences are not known and can only be estimated. The potential tragic outcome for the vulnerable group of pancreatic cancer patients highlights the urgency of timely healthcare decisions to be addressed in the future.

Sections du résumé

BACKGROUND
Coronavirus disease 19 (COVID-19) substantially affects cancer patients due to adverse outcomes and disruptions in cancer care. Recent studies have indicated the additional stress and anxiety burden arising from the pandemic and impairing quality of life in this vulnerable group of patients. However, patients with cancer represent a heterogenous group. Therefore, we conducted a study on patients with pancreatic cancer, requiring demanding surgical interventions and chemotherapy regimens due to its aggressive tumor biology, to explore the pandemic's impact on quality of life within this homogenous cohort.
METHODS
In a descriptive observational study, the quality of life of patients who had undergone pancreatic surgery for tumor resection at our institution between 2014 and the beginning of the pandemic in March 2020 was assessed. For HRQoL measurement, we used the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), comparing their situation before the pandemic and since its beginning. An additional self-developed questionnaire was applied to assess the life circumstances during the pandemic.
RESULTS
Our cohort included 26 patients. Scores from the survey in HRQoL revealed no significant changes over time between before and during the pandemic. A medium deterioration in HRQoL was apparent in social functioning, as well as a small deterioration in role functioning and emotional functioning. Worries concerning a potential impact of COVID-19 on personal health were expressed. Psychological limitations in QoL were mainly attributed to the pandemic, whereas physical limitations in QoL were rather associated with the underlying disease of pancreatic cancer.
CONCLUSION
The COVID-19 pandemic is causing considerable social and emotional distress among pancreatic cancer patients. These patients will benefit from psychological support during the pandemic and beyond. Long-time survivors of pancreatic cancer, such as those included in our cohort, appear to have improved resilience facing the psychosocial challenges of the pandemic. For pancreatic cancer, surgical care is considered the cornerstone of treatment. Prolonged delays in healthcare cause serious damage to mental and physical health. To date, the longer-term clinical consequences are not known and can only be estimated. The potential tragic outcome for the vulnerable group of pancreatic cancer patients highlights the urgency of timely healthcare decisions to be addressed in the future.

Identifiants

pubmed: 35329416
pii: ijerph19063731
doi: 10.3390/ijerph19063731
pmc: PMC8948872
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Références

J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Front Oncol. 2020 Aug 28;10:1553
pubmed: 33014800
Cancers (Basel). 2020 Aug 14;12(8):
pubmed: 32823999
Mayo Clin Proc. 2020 Aug;95(8):1805-1807
pubmed: 32753157
Front Psychiatry. 2019 Apr 05;10:208
pubmed: 31024362
Health Expect. 2021 Jun;24(3):978-990
pubmed: 33769657
BMC Public Health. 2021 May 1;21(1):837
pubmed: 33933042
Nat Rev Clin Oncol. 2021 Jan;18(1):1-2
pubmed: 33060841
Cancer Med. 2020 Dec;9(24):9205-9218
pubmed: 33078903
Int J Environ Res Public Health. 2021 Apr 27;18(9):
pubmed: 33925412
Psychiatry Res. 2020 May;287:112921
pubmed: 32240896
Value Health. 2015 Jan;18(1):110-5
pubmed: 25595241
Front Oncol. 2020 Jun 23;10:1128
pubmed: 32714873
Lancet Oncol. 2020 Aug;21(8):1035-1044
pubmed: 32702311
In Vivo. 2021 Jan-Feb;35(1):663-670
pubmed: 33402524
Oncologist. 2021 Feb;26(2):e342-e344
pubmed: 33210442
Psychooncology. 2020 Sep;29(9):1377-1379
pubmed: 32779778
Acta Oncol. 2021 Jan;60(1):4-12
pubmed: 33031010
Am J Clin Oncol. 2020 Jun;43(6):452-455
pubmed: 32304435
J Relig Health. 2020 Oct;59(5):2203-2204
pubmed: 32415426
BMC Musculoskelet Disord. 2020 Jun 30;21(1):415
pubmed: 32605559
Public Health Rep. 1994 Sep-Oct;109(5):665-72
pubmed: 7938388
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Transl Psychiatry. 2020 Jul 31;10(1):263
pubmed: 32737292
Clin Transl Oncol. 2020 Dec;22(12):2364-2368
pubmed: 32449128
ESMO Open. 2020 May;5(Suppl 3):
pubmed: 32423899
Brain Behav Immun. 2020 Jul;87:11-17
pubmed: 32240764
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
ESMO Open. 2020 Jun;5(Suppl 3):
pubmed: 32581069
Ann Surg. 2020 Aug;272(2):e87-e93
pubmed: 32675507
Cancer Cell. 2020 Nov 9;38(5):629-646
pubmed: 33049215
BMC Geriatr. 2021 Mar 22;21(1):199
pubmed: 33752614
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Eur J Cancer. 2012 Jul;48(11):1713-21
pubmed: 22418017
Clin Exp Metastasis. 2021 Apr;38(2):209-217
pubmed: 33634347
PLoS One. 2020 Jul 29;15(7):e0236572
pubmed: 32726344
J Gastrointest Surg. 2020 Oct;24(10):2357-2373
pubmed: 32607860

Auteurs

Andrea Alexander (A)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Stephen Fung (S)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Martin Eichler (M)

Clinic and Polyclinic for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, 01307 Dresden, Germany.

Nadja Lehwald-Tywuschik (N)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Vasuki Uthayakumar (V)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Sami-Alexander Safi (SA)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Christian Vay (C)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Hany Ashmawy (H)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Sinan Kalmuk (S)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Alexander Rehders (A)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Sascha Vaghiri (S)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Wolfram Trudo Knoefel (WT)

Department of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf and Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Duesseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH